MedTrace Logo

A Study to Investigate the Effects of Zovaglutide (ZT002 Injection) on QTc Interval in Healthy Adults

NCT07697846 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-07-13

No results posted yet for this study

Summary

This study is designed to investigate the effect of treatment with Zovaglutide (ZT002 Injection) on the corrected cardiac QT interval relative to a placebo control in healthy participants.

Conditions

  • Overweight, Obesity

Interventions

DRUG

ZT002 injection

Subjects will receive subcutaneous injections of Zovaglutide (ZT002 Injection) once every two weeks.

DRUG

ZT002 injection matching placebo

Subjects will receive subcutaneous injections of ZT002 injection matching placebo once every two weeks.

Sponsors & Collaborators

  • Beijing QL Biopharmaceutical Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Quankun Zhuang, Doctor · Beijing GoBroad Hospital

  • Xuemei Liu, Doctor · Beijing GoBroad Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-18
Primary Completion
2027-01-13
Completion
2027-03-24

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07697846 on ClinicalTrials.gov